Since EGFR amplification or activating mutations [1–3] are the most common genetic aberrations associated with malignant glioma, a combination therapy with anti-AR agent and EGFR inhibitor might have a beneficial effect in GBM especially in tumors that carry the AR variant and are known to be activated via signal transduction pathways, such as the EGFR pathway [17–19]. The gene discussed is AR; the disease is malignant glioma.